This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $506.17, moving +0.63% from the previous trading session.
Thermo Fisher Scientific (TMO) Stock Moves -0.8%: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $501.59 in the latest trading session, marking a -0.8% move from the prior day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Thermo Fisher Scientific (TMO) Stock Moves -0.76%: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $504.89, moving -0.76% from the previous trading session.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $507.73 in the latest trading session, marking a -1.51% move from the prior day.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $510.99, marking a -0.77% move from the previous day.
Thermo Fisher (TMO) to Advance Clinical Research With New Pact
by Zacks Equity Research
Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies.
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
by Zacks Equity Research
Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $536.70 in the latest trading session, marking a -0.98% move from the prior day.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $557.10, marking a -0.34% move from the previous day.
Steris (STE) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Thermo Fisher (TMO) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch
by Zacks Equity Research
Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.
Thermo Fisher (TMO) Launches New Chromosomal Microarray
by Zacks Equity Research
Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.
Thermo Fisher (TMO) Business Hurt by Low COVID Sales, FX Woe
by Zacks Equity Research
Thermo Fisher (TMO) is witnessing headwinds in the government and academic end markets.
Thermo Fisher (TMO) Completes the CorEvitas Acquisition
by Zacks Equity Research
Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
by Zacks Equity Research
Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.
Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.
Thermo Fisher (TMO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thermo Fisher Scientific (TMO) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of -5.16% and 2.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
MedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and More
by Urmimala Biswas
MedTech companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how DGX, TMO, EW and ALGN fare this time.
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $523.68, moving -0.3% from the previous trading session.